Juli 2021

ETAP-Lab will present its new Alzheimer's model in the aged mouse at the Alzheimer's Association International Conference, to be held in Denver (USA) from 26 to 30 July 2021. Our expert, Dr. Ahmad Allouche, will be there to answer your questions about our in vitro and in vivo models of Alzheimer's disease, based on the use of human A-Beta 1-42 oligomers. Our poster entitled "New Alzheimer models for drug screening, based on improved human amyloid beta (1-42) oligomer preparations" (number #54152), presents

Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an important milestone towards a more relevant and physiological model of Alzheimer’s disease for drug screening and mechanistic studies. For more information download the Application Note #alzheimer #DrugScreening #microfluidics #neuroscience

The poster we presented at the Alzheimer’s Association International Conference is now available on the ETAP-Lab website; it’s all about our innovative in vitro and in vivo models of Alzheimer's disease, which are based on the use of human A-Beta 1-42 oligomers. The poster focuses on the main results of the characterisation of the model in the aged mouse. This reproducible and translational model is a new tool for the evaluation of compounds targeting the early stages of Alzheimer's disease. We are